<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33641560</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7-8</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Compensatory metabolic and central respiratory drive mechanisms in ALS.</ArticleTitle><Pagination><StartPage>585</StartPage><EndPage>587</EndPage><MedlinePgn>585-587</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1876732</ELocationID><Abstract><AbstractText><i>Introduction</i>: Airway pressure in the first 100&#x2009;ms of an occluded inspiration (P0.1) evaluates respiratory center activity. Its increase compensates for respiratory muscle weakness in amyotrophic lateral sclerosis (ALS). We aimed to evaluate if an exhaustion over disease progression emerges. <i>Methods</i>: Consecutive ALS patients with P0.1 at baseline (T0) above 90th percentile for the whole population were included. There were two patient categories within this population: G1 patients had respiratory function tests (RFT) at T0 and 6 months later (T1); G2 patients were immediately adapted to noninvasive ventilation at T0. Functional ALS rating scale (ALSFRS) and its subscores, RFT including maximal inspiratory pressure (MIP), P0.1 percentage (%P0.1), P0.1/MIP, blood gas analyses, phrenic nerve motor amplitude and nocturnal pulsed oximetry (NPO) were compared at T0 between groups (Mann-Whitney <i>U</i> test) and longitudinal progression in G1 was assessed (Wilcoxon test). <i>p</i>&#x2009;&lt;&#x2009;0.05 was taken as significant. <i>Results</i>: Forty-nine patients were studied: 13 men, mean disease duration 17.1&#x2009;&#xb1;&#x2009;19.5 months, 21 with spinal-onset; 27 bulbar-onset; one with respiratory presentation. In G1, there was a progressive deterioration in all variables but P0.1/MIP did not significantly change (<i>p</i>&#x2009;=&#x2009;0.394). PCO<sub>2</sub> (<i>p</i>&#x2009;=&#x2009;0.045) and bicarbonate ion (HCO<sub>3</sub><sup>-</sup><i>p</i>&#x2009;=&#x2009;0.054) increased. In G2, the ALSFRS (<i>p</i>&#x2009;=&#x2009;0.049) scores were lower, PCO<sub>2</sub> (<i>p</i>&#x2009;=&#x2009;0.057) and HCO<sub>3</sub><sup>-</sup> (<i>p</i>&#x2009;=&#x2009;0.016) higher, and reduced arterial oxygen saturation (SpO<sub>2</sub>&lt;90%) at NPO (<i>p</i>&#x2009;=&#x2009;0.007). <i>Discussion</i>: Patients with high central respiratory drive responses did not develop a short-term "exhaustion phenomenon". Both metabolic and central respiratory mechanisms interact to compensate for respiratory muscle weakness. The role of spasticity and the respiratory-metabolic-renal buffering system deserves further studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0727-5897</Identifier><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swash</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8717-8914</Identifier><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7556-0158</Identifier><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio de Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072277" MajorTopicYN="N">Maximal Respiratory Pressures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010791" MajorTopicYN="N">Phrenic Nerve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">central respiratory drive</Keyword><Keyword MajorTopicYN="N">metabolic compensation</Keyword><Keyword MajorTopicYN="N">mouth occlusion pressure</Keyword><Keyword MajorTopicYN="N">progressive respiratory failure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>1</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33641560</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1876732</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>